Expanding targeted therapies for NSCLC.
The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer. While dabrafenib shows some promise, the preliminary results for neratinib with or without temsirolimus are insufficient to determine whether patients may benefit.